Mubadala Secures Full Ownership of UCB’s China Pharma Business

Mubadala Investment Company, in collaboration with CBC Group, has taken full control of UCB Pharma’s mature business in China. This strategic move involves the acquisition of UCB’s neurology and allergy portfolios, including the Zhuhai manufacturing facility. UCB, a Belgium-based biopharma leader, continues to focus on expanding its presence in China, especially in neurology and immunology. The deal aligns with Mubadala’s broader strategy to grow its healthcare investments across Asia, particularly in high-growth sectors like pharmaceuticals. The transaction is set to close by Q4 2024, pending regulatory approvals.